JP2006516141A - 抗高脂血症剤および抗高血圧剤としてのリポキシゲナーゼ阻害剤 - Google Patents

抗高脂血症剤および抗高血圧剤としてのリポキシゲナーゼ阻害剤 Download PDF

Info

Publication number
JP2006516141A
JP2006516141A JP2004563692A JP2004563692A JP2006516141A JP 2006516141 A JP2006516141 A JP 2006516141A JP 2004563692 A JP2004563692 A JP 2004563692A JP 2004563692 A JP2004563692 A JP 2004563692A JP 2006516141 A JP2006516141 A JP 2006516141A
Authority
JP
Japan
Prior art keywords
diet
hff
lipoxygenase inhibitor
derivative
hypertension
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004563692A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006516141A5 (enExample
Inventor
アレン，ジェフリー
ケリー，グレン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Insmed Inc
Original Assignee
Insmed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Insmed Inc filed Critical Insmed Inc
Publication of JP2006516141A publication Critical patent/JP2006516141A/ja
Publication of JP2006516141A5 publication Critical patent/JP2006516141A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2004563692A 2002-12-19 2003-12-18 抗高脂血症剤および抗高血圧剤としてのリポキシゲナーゼ阻害剤 Pending JP2006516141A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US43441202P 2002-12-19 2002-12-19
US51110303P 2003-10-15 2003-10-15
US10/734,625 US20040198800A1 (en) 2002-12-19 2003-12-15 Lipoxygenase inhibitors as hypolipidemic and anti-hypertensive agents
PCT/US2003/040254 WO2004058240A1 (en) 2002-12-19 2003-12-18 Lipoxygenase inhibitors as hypolipidemic and anti-hypertensive agents

Publications (2)

Publication Number Publication Date
JP2006516141A true JP2006516141A (ja) 2006-06-22
JP2006516141A5 JP2006516141A5 (enExample) 2007-02-01

Family

ID=32686074

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004563692A Pending JP2006516141A (ja) 2002-12-19 2003-12-18 抗高脂血症剤および抗高血圧剤としてのリポキシゲナーゼ阻害剤

Country Status (6)

Country Link
US (1) US20040198800A1 (enExample)
EP (1) EP1572185A4 (enExample)
JP (1) JP2006516141A (enExample)
AU (1) AU2003303331A1 (enExample)
CA (1) CA2510295A1 (enExample)
WO (1) WO2004058240A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060106014A1 (en) * 2004-10-14 2006-05-18 Sekhar Boddupalli Methods for treating diabetes
US7405302B2 (en) 2005-10-11 2008-07-29 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (FLAP) inhibitors
US20070219206A1 (en) * 2005-11-04 2007-09-20 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (flap) inhibitors
GB2431927B (en) * 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
US20070244128A1 (en) * 2005-11-04 2007-10-18 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (flap) inhibitors
US8399666B2 (en) * 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
US7977359B2 (en) * 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
US20070225285A1 (en) * 2005-11-04 2007-09-27 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (flap) inhibitors
WO2007072503A2 (en) * 2005-12-21 2007-06-28 Panacea Biotec Ltd. Combinations for managing inflammation and associated disorders
TW200920369A (en) * 2007-10-26 2009-05-16 Amira Pharmaceuticals Inc 5-lipoxygenase activating protein (flap) inhibitor
SG190667A1 (en) * 2008-05-23 2013-06-28 Panmira Pharmaceuticals Llc 5-lipoxygenase-activating protein inhibitor
US8546431B2 (en) 2008-10-01 2013-10-01 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
NZ807894A (en) 2009-04-29 2025-08-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
WO2014138922A1 (en) * 2013-03-15 2014-09-18 Indanio Bioscience Inc. Uses for idebenone and related benzoouinones in ppar-related diseases and conditions

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60142981A (ja) * 1983-12-28 1985-07-29 Yoshitomi Pharmaceut Ind Ltd ３−インド−ルカルボキサミド誘導体
JPS6165869A (ja) * 1984-09-07 1986-04-04 Kyowa Hakko Kogyo Co Ltd キノリン−ｎ−オキシド誘導体
JPH0558893A (ja) * 1991-02-08 1993-03-09 Pfizer Inc コレステロール低下組成物
JP2783655B2 (ja) * 1990-07-02 1998-08-06 帝人株式会社 ヒドロキサム酸誘導体
JP2976885B2 (ja) * 1995-06-01 1999-11-10 三共株式会社 縮合複素環化合物
WO2002089791A2 (de) * 2001-04-30 2002-11-14 Zouboulis Christos C Behandlung der akne mit lipoxygenase inhibitoren
WO2002098893A1 (en) * 2001-05-30 2002-12-12 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxypyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate therefor

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4294926A (en) * 1979-06-15 1981-10-13 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4319039A (en) * 1979-06-15 1982-03-09 Merck & Co., Inc. Preparation of ammonium salt of hypocholesteremic fermentation product
US4231938A (en) * 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
US4393075A (en) * 1980-04-14 1983-07-12 Takeda Chemical Industries, Ltd. Quinone compounds and their use in suppressing the production of SRS-A in mammals
MX7065E (es) * 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
JPS5889191A (ja) * 1981-11-20 1983-05-27 Sankyo Co Ltd ３−ヒドロキシ−ｍｌ−２３６ｂ誘導体の製造法
US5354772A (en) * 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US4486593A (en) * 1983-01-19 1984-12-04 The Upjohn Company 2-,3-, or 4-Pyridinylmethylamino arylic acids as thromboxane A2 synthetase and 5-lipoxygenase inhibitors
IE59397B1 (en) * 1985-03-16 1994-02-23 Wellcome Found New aryl derivatives
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US4820850A (en) * 1987-07-10 1989-04-11 Merck & Co., Inc. Process for α-C-alkylation of the 8-acyl group on mevinolin and analogs thereof
JP3003148B2 (ja) * 1989-01-05 2000-01-24 藤沢薬品工業株式会社 チアゾール化合物、その製造法およびそれを含有する医薬組成物
US5250547A (en) * 1991-08-29 1993-10-05 Syntex (U.S.A.) Inc. Benzopyran derivatives
HU9203780D0 (en) * 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
US6191169B1 (en) * 1992-08-28 2001-02-20 City Of Hope Human leukocyte 12-lipoxygenase and its role in the pathogenesis of disease states
US5298627A (en) * 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60142981A (ja) * 1983-12-28 1985-07-29 Yoshitomi Pharmaceut Ind Ltd ３−インド−ルカルボキサミド誘導体
JPS6165869A (ja) * 1984-09-07 1986-04-04 Kyowa Hakko Kogyo Co Ltd キノリン−ｎ−オキシド誘導体
JP2783655B2 (ja) * 1990-07-02 1998-08-06 帝人株式会社 ヒドロキサム酸誘導体
JPH0558893A (ja) * 1991-02-08 1993-03-09 Pfizer Inc コレステロール低下組成物
JP2976885B2 (ja) * 1995-06-01 1999-11-10 三共株式会社 縮合複素環化合物
JP2000001487A (ja) * 1995-06-01 2000-01-07 Sankyo Co Ltd 縮合複素環誘導体
WO2002089791A2 (de) * 2001-04-30 2002-11-14 Zouboulis Christos C Behandlung der akne mit lipoxygenase inhibitoren
WO2002098893A1 (en) * 2001-05-30 2002-12-12 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxypyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate therefor

Also Published As

Publication number Publication date
EP1572185A4 (en) 2009-02-25
WO2004058240A1 (en) 2004-07-15
AU2003303331A1 (en) 2004-07-22
CA2510295A1 (en) 2004-07-15
EP1572185A1 (en) 2005-09-14
US20040198800A1 (en) 2004-10-07

Similar Documents

Publication Publication Date Title
Hu et al. Anti-stress effects of dehydroepiandrosterone: protection of rats against repeated immobilization stress-induced weight loss, glucocorticoid receptor production, and lipid peroxidation
JP2006516141A (ja) 抗高脂血症剤および抗高血圧剤としてのリポキシゲナーゼ阻害剤
AU2007235145B2 (en) Combination treatment of metabolic disorders
JP2010519196A (ja) 経粘膜送達を高めるための組成物および方法
JPH0825875B2 (ja) ３―グアニジノプロピオン酸の代謝障害の治療用組成物
WO2000064431A9 (en) Pharmaceutical compositions of tetrac and methods of use thereof
UA122719C2 (uk) Лікування внутрішньопечінкових холестатичних захворювань
US20080153827A1 (en) Method for the Treatment or Prevention of Cardiac Hypertrophy
CN114007607A (zh) 用于治疗神经变性疾病的材料和方法
US20080306157A1 (en) Therapeutic intervention to MIMIC the effect of caloric restriction
JPH06504278A (ja) ヒトの高い血糖値を低下させる方法
US10376484B2 (en) Combination of bezafibrate and of resveratrol or resveratrol derivatives for the treatment and prevention of diseases involving a mitochondrial energy dysfunction
AU2002251080B2 (en) Oestrogen and fatty acid monoester as a hypolipidaemic and antidiabetic agent
US20190240172A1 (en) Pharmaceutical composition for preventing or treating diabetes and/or hyperlipidemia comprising midodrine or pharmaceutically acceptable salt thereof as active ingredient
Bao et al. Curcumin ameliorates renal impairment in a diabetic rat model
EP4497439A1 (en) Compounds for the treatment or prevention of gout
WO2004096278A1 (ja) アディポネクチン産生増強剤
JP7427199B2 (ja) 代謝改善剤
US20060111442A1 (en) Use of methyl pyruvate to increase cellular energy production downstream of glycolysis for the PARP-1 ablation of HIV without necrotic cell death caused by continuous, chronic PARP-1 activation through the concomitant depletion of ATP and NAD.
US20190099384A1 (en) Methods for inhibiting conversion of choline to trimethylamine (tma)
Anionye et al. Protective Effects of Cellgevity® Against High Fructose Diet-Induced Kidney Dysfunction and Hyperuricaemia in Wistar Rats
Shibata et al. Triglyceride-lowering effect of a novel insulin-sensitizing agent, JTT-501
WO2004014427A1 (ja) 血液脂質を低下させるための医薬組成物
EP4547244A1 (en) Scd1 inhibitors for treating liver disease
JP4894993B2 (ja) 糖尿病の予防又は治療剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061205

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061205

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100223

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100521

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100528

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100621

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20101012